← Back to catalogue
ENQUIRE ABOUT THIS RESEARCH COMPOUND →
Endocrine Research
PT-141
10mg
PT-141, also known as bremelanotide, is explored in research involving central melanocortin-receptor signalling.
Research focusMelanocortin-receptor research
PresentationLyophilised peptide · 10mg · 3 mL vial
Research overview
PT-141 is bremelanotide, a melanocortin-receptor agonist developed from melanotan-related research. Its pharmacology is centrally mediated rather than acting primarily through peripheral vascular mechanisms.
Evidence status
Established human clinical literature
Bremelanotide has human clinical-trial and regulatory literature. Research pages should distinguish the molecule’s established evidence from unsupported uses outside studied contexts.
Research use only. Not for human consumption. This page is educational and does not provide medical advice or dosing guidance.
Areas under investigation
- Melanocortin-receptor pharmacology
- Central neural signalling
- Sexual-function research
Explore the scientific literature
For primary-source reading, search the indexed biomedical literature and registered clinical studies. These links are provided as research gateways rather than endorsements of any particular finding.
PUBLISHED STUDY MAP
See a source-linked study design for PT-141 / Bremelanotide: population, route, timeframe and endpoint — without dosing recommendations.
OPEN STUDY MAP →